Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Adrenocortical Carcinoma
NCT03612232Phase 2Active, not recruiting
- Start
- Jun 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in adrenocortical carcinoma (ACC). Started Jun 2019; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT03612232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612232.